eligibility_summary
Adults ≥18 with metastatic/recurrent EG adenocarcinoma, ECOG 0–1, life ≥4 mo. Leukapheresis: consent, MSLN ≥25% IHC, stage IV peritoneal disease, prior therapy (HER2+ got anti‑HER2), measurable disease, adequate labs, infection screen negative, toxicities ≤1. Lymphodepletion/CAR‑T: similar, ANC ≥1.5, Hb ≥8, longer washouts. Exclude: pregnancy,active HIV/HBV/HCV/other cancer,prior CAR‑T/mesothelin,surgery<28d,untreatedCNSmets,autoimmune/steroids,cardiac/ILD,SpO2<90%,infection,livevaccine<8w.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06623396 tests M28z1XXPD1DNR CAR T cells—an autologous, genetically modified cellular therapy—delivered intraperitoneally in mesothelin-positive esophagogastric adenocarcinoma with peritoneal carcinomatosis (Phase I, single arm). Mechanism: patient T cells are engineered to express a mesothelin-specific chimeric antigen receptor with CD28 costimulation and a tuned CD3ζ (1XX) signaling domain to balance activation/persistence, plus a PD-1 dominant-negative receptor to resist PD-1/PD-L1–mediated inhibition. Targets: mesothelin-expressing tumor cells in the peritoneum, T-cell activation pathways, PD-1 checkpoint signaling.